MODERN POSSIBILITIES OF APPLICATION OF PREPARATION NAVELBINE® IN THE TREATMENT OF METASTATIC BREAST CANCER

MODERN POSSIBILITIES OF APPLICATION OF PREPARATION NAVELBINE® IN THE TREATMENT OF METASTATIC BREAST CANCER

Drug therapy of disseminated forms of breast cancer involves the use of monoand polychemotherapy with the possible combination with target-therapy in various clinical situations. The article presents the choices of treatment approaches, demonstrated the efficacy and safety of chemotherapeutic regime...

Full description

Bibliographic Details
Main Author:	L. V. Bolotina
Format:	Article
Language:	Russian
Published:	QUASAR, LLC 2016-06-01
Series:	Исследования и практика в медицине
Subjects:	vinorelbine metastatic breast cancer (mbc) metronomic chemotherapy
Online Access:	https://www.rpmj.ru/rpmj/article/view/141

Similar Items

Immunomodulatory effects of metronomic vinorelbine (mVRL), with or without metronomic capecitabine (mCAPE), in hormone receptor positive (HR+)/HER2-negative metastatic breast cancer (MBC) patients: final results of the exploratory phase 2 Victor-5 study
by: F. F. Pepe, et al.
Published: (2022-09-01)

A phase II study of a doublet metronomic chemotherapy regimen consisting of oral vinorelbine and capecitabine in Chinese women with HER2‐negative metastatic breast cancer
by: Yue Chai, et al.
Published: (2023-08-01)

Enhanced antitumor and anti-angiogenic effects of metronomic Vinorelbine combined with Endostar on Lewis lung carcinoma
by: Rong-Sheng Qin, et al.
Published: (2018-10-01)

A Systematic Review and Pooled Analysis of Studies of Oral Etoposide in Metastatic Breast Cancer
by: Ioannis A. Voutsadakis
Published: (2018-01-01)

Maintenance metronomic chemotherapy combined with conventional treatment for metastatic breast cancer patients
by: Sherif Elzawawy, et al.
Published: (2015-12-01)

Metronomic chemotherapy using capecitabine and cyclophosphamide in metastatic breast cancer – efficacy, tolerability and quality of life results from the phase II METRO trial
by: Karolina Larsson, F, et al.
Published: (2024-12-01)

Anti-tumor effects of low-dose metronomic vinorelbine in combination with alpelisib in breast cancer cells
by: Slavomir Krajnak, et al.
Published: (2023-01-01)

Anlotinib in combination with metronomic chemotherapy in HER2-negative metastatic breast cancer: an observational and retrospective study
by: Jiaxuan Liu, et al.
Published: (2025-01-01)

Clinical case of the use of oral metronomic vinorelbin in patient with metastatic Her2 negative breast cancer
by: M. A. Frolova, et al.
Published: (2021-08-01)

Oral vinorelbine and capecitabine as first-line therapy in metastatic breast cancer: a retrospective analysis
by: Maria Rosaria Valerio, et al.
Published: (2021-12-01)

Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
by: Alberto Alvarado-Miranda, et al.
Published: (2023-06-01)

Pyrotinib combined with metronomic etoposide in heavily pretreated HER2-positive metastatic breast cancer: a single-arm, phase II study
by: Jiaxuan Liu, et al.
Published: (2024-10-01)

Efficacy and safety of utidelone plus capecitabine in advanced first-line therapy for metastatic breast cancer: A multicenter real-world study
by: Pingping Bi, et al.
Published: (2023-12-01)

The efficiency and safety of low‐dose apatinib combined with oral vinorelbine in pretreated HER2‐negative metastatic breast cancer
by: Jia‐Yi Huang, et al.
Published: (2024-04-01)

Safety and efficacy study of oral metronomic capecitabine combined with pyrotinib in HER2-positive metastatic breast cancer: A phase II trial
by: Maiyue He, et al.
Published: (2023-12-01)

PERORAL FORMS OF CYTOSTATIC DRUGS IN THERAPY OF METASTATIC MAMMARY GLAND CANCER: ROLE IN CLINICAL PRACTICE
by: G. M. TELETAEVA, et al.
Published: (2016-12-01)

Oral vinorelbine: its role in advanced breast cancer pre-treated with anthracycline and taxane chemotherapies
by: Fausto Petrelli, et al.
Published: (2011-12-01)

Vinorelbine as First-Line Treatment in Stage IV Canine Primary Pulmonary Carcinoma
by: Valentina Rinaldi, et al.
Published: (2023-11-01)

Novel Effective Therapeutic Regimen for Recurrent/Metastatic Head and Neck Squamous Cell Cancer: Concurrent Triple Oral Metronomic Chemotherapy and Immunotherapy
by: Sewanti Limaye, et al.
Published: (2024-08-01)

Construction and validation of a prognostic nomogram in metastatic breast cancer patients of childbearing age: A study based on the SEER database and a Chinese cohort
by: Xiang Ma, et al.
Published: (2022-11-01)

David Slays Goliath: Exceptional Efficacy of Oral Vinorelbine in Conquering Metastatic Finger Angiosarcoma
by: Te-Lin Hsu, et al.
Published: (2024-01-01)

Hexachlorobenzene as a differential modulator of the conventional and metronomic chemotherapy response in triple negative breast cancer cells
by: Yamila Sanchez, et al.
Published: (2024-03-01)

Metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with trastuzumab (HEX) as first line therapy of HER-2 positive advanced breast cancer: A phase II trial of the Gruppo Oncologico Italia Meridionale (GOIM)
by: Laura Orlando, et al.
Published: (2020-10-01)

Clinical Outcomes of Patients Treated with Ribociclib in Combination with Aromatase Inhibitors or Fulvestrant for HR-Positive, HER2-Negative Metastatic Breast Cancer, Real-World Data from a Low-Resourced Country
by: Abdel-Razeq H, et al.
Published: (2024-09-01)

Assessing chemotherapy dosing strategies in a spatial cell culture model
by: Dhruba Deb, et al.
Published: (2022-11-01)

Healthcare costs in women with metastatic breast cancer receiving chemotherapy as their principal treatment modality
by: Borker Rohit, et al.
Published: (2011-06-01)

Phase II randomized trial comparing metronomic anthracycline-containing chemotherapy versus standard schedule in untreated HER2 negative advanced breast cancer: activity and quality of life results of the GOIM 21003 trial
by: Laura Orlando, et al.
Published: (2024-06-01)

Comparing pyrotinib with trastuzumab and pertuzumab with trastuzumab for HER2-positive metastatic breast cancer: a retrospective, multicenter analysis
by: Shuhui You, et al.
Published: (2023-12-01)

Metronomic chemotherapy regimens in oncology
by: M. Yu. Fedyanin, et al.
Published: (2016-04-01)

Impressive response to oral metronomic chemotherapy in ovarian cancer
by: Dinesh Shet, et al.
Published: (2022-12-01)

Clinical relevance of the combined analysis of circulating tumor cells and anti-tumor T-cell immunity in metastatic breast cancer patients
by: Elena Muraro, et al.
Published: (2022-08-01)

Metronomic chemotherapy: bridging theory to clinical application in canine and feline oncology
by: Gonçalo N. Petrucci, et al.
Published: (2024-06-01)

Activity and safety of KEES - an oral multi-drug chemo-hormonal metronomic combination regimen in metastatic castration-resistant prostate cancer
by: Mustafa Asowed, et al.
Published: (2023-04-01)

Metronomic chemotherapy and drug repurposing: A paradigm shift in oncology
by: Nusrat Jan, et al.
Published: (2024-02-01)

Adverse events of bevacizumab for triple negative breast cancer and HER-2 negative metastatic breast cancer: A meta-analysis
by: Xueqiong Xun, et al.
Published: (2023-01-01)

Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated with Metronomic Cyclophosphamide: A Clinical and Translational Prospective Study
by: Mery B, et al.
Published: (2023-04-01)

Survival analysis of bevacizumab plus taxane treatment in luminal metastatic breast cancer
by: Serafin Morales Murillo, et al.
Published: (2021-03-01)

Establishment and validation of an individualized macrophage-related gene signature to predict overall survival in patients with triple negative breast cancer
by: Peng Su, et al.
Published: (2021-11-01)

Novel method for highly multiplexed gene expression profiling of circulating tumor cells (CTCs) captured from the blood of women with metastatic breast cancer
by: Morvarid Farhang Ghahremani, et al.
Published: (2023-06-01)

Anti-Cancer Treatment Strategies in the Older Population: Time to Test More?
by: Antonino C. Tralongo, et al.
Published: (2021-04-01)